Income Tax at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's income tax?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported income tax of $10.09M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's income tax changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's income tax increased by 43.6% year-over-year, from $7.03M to $10.09M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's income tax?
- Over 3 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's income tax has grown at a 178.3% compound annual growth rate (CAGR), from $1.39M to $29.86M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.